跳至主要内容
临床试验/NCT05417035
NCT05417035已完成不适用

Pubertal Replacement In Boys Study Pubertal Induction in Boys With Delayed Puberty: Comparison Between Testosterone Enanthate and Testosterone Undecanoate Treatment.

NU-Hospital Organization, Sweden0 个研究点目标入组 27 人开始时间: 2014年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
27
主要终点
Testicular Volume 8ml

研究概览

简要总结

In this prospective open clinical study, Pubertal Replacement in Boys Study (PRIBS), boys 14-16 years with delayed puberty in terms of slow pubertal progression, were randomized to SoC treatment with TE: Testostoviron depot® 75 mg intramuscularly (i.m) / month (6 injections), or low dose TU: Nebido® 250mg i.m. / 3 months (2 injections). Our goal was to implement a study similar to clinical routine.

详细描述

Boys 14-16 years with pubertal delay were randomized to standard treatment with TE (Testosterone enanthat 75mg /month 6 injections)or newer treatment TU(Testosterone Undecanooat 250mg 2 injections 3 months apart) for pubertal induction. Our study PRIBS (pubertal replacement in boys study) was academically sponsored, monitored and approved by the medical products agency in Sweden. Between 2014 -08 and 2019-07 27 boys were randomized to treatment with TE (12 boys) or TU (15 boys). Testosterone levels were measured twice before study start and after 2,7,30,60,90,180 and 365 days. Boys with delayed puberty > 14 years with morning testosterone levels 0,5 - 3 Nmol/L and testicular volume ≤ 6 mL were included.Primary Outcome was testicular enlargement ≥ 8mL after 12 months. The new treatment was considered clinically similar if the treatment result were in the 80-125% interwall of the traditional group. Fishers exact chi square test was used for this analysis. Our intention was to recruit 20 boys in each armInformed consent was signed before study start by parents and assent by the boys. PRIBS was approved by the regional ethic committee 2012-09-14 Dnr 506-12 and approved by Union Drug Regulating Authorities Clinical Trials Database EudraCT nr 2012-002337-11 and the Swedish drug authorities (Läkemedelsverket) All study personal was trained in ICH GCP (good clinical practice).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Male
接受健康志愿者

入选标准

  • • Signed informed consent
  • Two morning testosterone values (07.30-09.00) of 1-3 nmol/L and at start < 4 mmol/L ¹
  • Testicular volume 4-6 mL bilaterally²

排除标准

  • • Growth spurt
  • Untreated hypothyroidism, celiac disease or steroid medication
  • Training doses > 10 hours a week
  • Use of anabolic steroids or other drugs

研究组 & 干预措施

Nebido

Experimental

i.m 250 mg/3months 2 injectionjs

干预措施: Nebido (Drug)

Testoviron Depot

Active Comparator

i.m75mg/month 6 injections

干预措施: Nebido (Drug)

结局指标

主要结局

Testicular Volume 8ml

时间窗: 12 months after induction

Evaluation by palpating the testicles

次要结局

未报告次要终点

研究者

发起方
NU-Hospital Organization, Sweden
申办方类型
Other
责任方
Principal Investigator
主要研究者

Martin Österbrand

Paediatrician

NU-Hospital Organization, Sweden

相似试验